Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $51.0152W HIGH $89.83
Volume
616.08 K
Value Traded
181.13 M
Short % Float
4.41%
Days to Cover
1.7
+5.73%Week
+8.7%1 Month
-12.52%3 Month
-4.43%6 Month
-35.96%5 Year
+773.72%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
11.68 B
EPS (TTM)
3.00
P/E Ratio
20.50
Ent. Value
14.07 B
Total Shares
190.16 M
Float Shares
188.94 M
Insiders
0.64%
Institutions
111.84%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
COO Catalyst Timeline
Dated clinical, regulatory and corporate events for The Cooper Companies, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for The Cooper Companies, Inc.
50Total events
3Upcoming
11Tier-1 (high impact)
2013 to 2026Coverage
Upcoming catalysts 2
Event history 41
●Quarterly UpdateCorporate
Completion of strategic review process and announced actions to enhance shareholder value
●Timing GuidancePresentation
Completed strategic review process and announced actions to enhance shareholder value
▲Corporate ApprovalCorporate
Board approved expansion of share repurchase authorization from $2 billion to $3 billion
●Quarterly UpdateCorporate
Reaffirmed long-term free cash flow objective exceeding $2.2B for FY2026-2028
▼Quarterly UpdateCorporate
Recorded $271.6M pre-tax litigation charge related to fertility media recall
◆Oral PresentationPresentation
CooperCompanies to participate in Wells Fargo Healthcare Conference
◆Oral PresentationPresentation
CooperCompanies to present at William Blair Growth Stock Conference
◆AcquisitionCorporate
CooperCompanies signs binding letter of intent to acquire Cook Medical's Reproductive Health business
◆Quarterly UpdateCorporate
Q4 and full year 2017 earnings report with Hurricane Maria financial impact
▲Manufacturing MilestoneCMC / Inspection
CooperVision Juana Diaz facility restored to ~90% manufacturing operations after Hurricane Maria
◆AcquisitionPARAGARDCorporate
Cooper enters definitive agreement to acquire PARAGARD IUD from Teva
contraceptionsource ↗
◆Management ChangeCorporate
CFO Gregory W. Matz to retire; Albert G. White named successor effective November 1, 2016
●Management ChangeCorporate
Appointment of Colleen Jay and William Kozy to Board of Directors
●Quarterly UpdateCorporate
The Cooper Companies announces fiscal third quarter 2015 financial results
◆AcquisitionCorporate
Cooper Companies announces definitive agreement to acquire Sauflon Pharmaceuticals Ltd
●Quarterly UpdateCorporate
The Cooper Companies announces fiscal second quarter 2014 financial results
▲Equity OfferingCorporate
Board authorized additional $200M share repurchase, total program up to $500M
▲Product LaunchMyDayPost-Market
Launch of MyDay branded single-use silicone hydrogel lens
vision correctionsource ↗
▼Program DiscontinuationAimeDiscontinuedCorporate
Agreement to divest Aime business in Japan
rigid gas permeable contact lens and solutionssource ↗
Past FDA Catalysts and PDUFA Decisions
How COO actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2024-06-28 | Paragard T 380a (copper) | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 52%
Mid Cap(rank 342 of 657)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| TH-1 Dendritic Cell Immunotherapy Monoclonal antibodyCompletedNCT04552886 | Glioblastoma | Phase 1 | COMPLETED | 17 | Nov 1, 2023 |
Clinical Trial Results
Readouts, endpoints and source filings for every COO program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Kurzius Lawrence ErikDirector | Buy | 10,000 31,099 held | $54.93 | 09/16/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in COO
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PFM HEALTH SCIENCES, LP | 1.4 % (27.3 %) | 15.84 M | 220.89 K | 30.07% ( 51.06 K) |
COO Institutional Ownership Trends
COO Short Interest
Shares sold short, counted twice a month.
4.41%
Short % of Float
of tradable shares sold short
8.3M
Shares Sold Short
-16.8% vs prior count
1.7 Low
Days to Cover
trading days of normal volume to buy every short share back
5.0M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How COO ranks across every disease it competes in
Competitive Position is a premium feature
See how COO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCOO News
COO▼ -14.7%on this news
CooperCompanies Announces Third Quarter 2026 Results
CooperCompanies reported a 1% year-over-year revenue increase to $1.066 billion for Q3 2026, driven by a significant tax benefit that boosted GAAP EPS to $2.24. Non-GAAP EPS rose 4% to $1.15, while free cash flow increased by 66% to $273 million. Despite these positive results, inventory reductions at CooperVision weighed on performance, indicating potential challenges ahead.
Read more →COOCooperCompanies Announces Release Date for Third Quarter 2026
CooperCompanies has announced the release date for its third quarter 2026 financial results, which will be reported on September 9, 2026. Following the announcement, a conference call will be held to discuss the results and corporate developments. The company continues to emphasize its commitment to healthcare through its business units.
Read more →COOCooperCompanies Releases 2025 Corporate Sustainability Report with Scope 3 Emissions Disclosure
CooperCompanies has released its 2025 Corporate Sustainability Report, highlighting its commitment to sustainability through the disclosure of Scope 3 greenhouse gas emissions. The report details innovations in vision care and women's health, including the MADE BETTER™ platform and new reproductive health solutions. The company aligns with major sustainability frameworks, showcasing its dedication to responsible practices.
Read more →COOCooperCompanies Announces Second Quarter 2026 Results
CooperCompanies reported strong financial results for Q2 2026, with revenues reaching $1.082 billion, an 8% increase from the previous year. Non-GAAP diluted EPS rose to $1.21, up 26% year-over-year. However, GAAP EPS fell to $(0.40) due to a significant litigation charge related to a product recall. The company also resolved most claims associated with the recall, allowing for a strategic review moving forward.
Read more →COOCooperCompanies Appoints Paul Keel to its Board of Directors
CooperCompanies has appointed Paul Keel as an independent director, effective July 1, 2026. Keel brings extensive experience from his roles at Envista Holdings and Smiths Group, which will be valuable for the company's strategic execution. He will also serve on the Audit Committee, further enhancing the Board's capabilities.
Read more →COOCooperCompanies Announces Release Date for Second Quarter 2026
CooperCompanies has announced that it will release its financial results for the second quarter of 2026 on June 4, 2026. Following the announcement, a conference call will be held to discuss the results and corporate developments. Interested parties can join the call using the provided dial-in number and access the webcast online.
Read more →COOCooperVision Launches MiSight® 1 day in Japan; Becomes First Myopia Control Contact Lens in Leading Vision Care Market
CooperVision has launched its MiSight® 1 day myopia control contact lens in Japan, marking a significant advancement in myopia management for children. This lens is the first of its kind authorized by Japan's Ministry of Health for myopia correction and progression control. With a high prevalence of myopia among Japanese children, this launch aims to improve their vision and quality of life.
Read more →COOCooperCompanies Appoints Walter M Rosebrough, Jr. to its Board of Directors
CooperCompanies has appointed Walter M Rosebrough, Jr. as an independent director, effective January 3, 2026. This appointment is part of a cooperation agreement with Browning West, which aims to enhance the board's effectiveness. Rosebrough's extensive experience in the medical device sector is expected to contribute to the company's strategic vision and shareholder value.
Read more →COOCooperCompanies Announces Release Date for Fourth Quarter and Full Year 2025
CooperCompanies has announced the release date for its fourth quarter and full year 2025 financial results, scheduled for December 4, 2025. The company will host a conference call at 5:00 PM ET to discuss these results and other corporate developments. Interested parties can join the call using the provided dial-in number and conference ID.
Read more →COOCooperCompanies Announces Expanded Share Repurchase Program
CooperCompanies has announced a $1 billion increase to its share repurchase program, bringing the total to $2 billion. This decision reflects the company's strong balance sheet and commitment to returning capital to shareholders. The timing and amount of repurchases will depend on market conditions, and the program has no termination date.
Read more →COO▼ -12.9%on this news
CooperCompanies Announces Third Quarter 2025 Results
CooperCompanies announced its fiscal third quarter results, highlighting strong margins and double-digit earnings growth despite revenues falling short of expectations. CEO Al White expressed confidence in the company's operational performance and raised earnings guidance for the upcoming quarter. The company anticipates improved revenue driven by its MyDAY® product line in fiscal 2026.
Read more →COOCooperCompanies to Participate in the Wells Fargo Healthcare Conference
CooperCompanies will participate in the Wells Fargo Healthcare Conference on September 3, 2025. Al White, the President and CEO, will represent the company during the session. The event will be available via webcast for investors and interested parties. CooperCompanies is known for its contributions to the medical device sector, particularly in vision and women's healthcare.
Read more →COOCooperCompanies’ 2024 Sustainability Report Showcases Efforts that Benefit People and the Planet
CooperCompanies has released its 2024 Sustainability Report, highlighting its commitment to sustainability and positive impact on society and the environment. The report details partnerships aimed at reducing plastic use, certifications achieved, and investments in employee development. It aligns with the Sustainability Accounting Standards Board standards, emphasizing the company's dedication to responsible practices.
Read more →COOCooperCompanies to Participate in the William Blair Growth Stock Conference
CooperCompanies will participate in the William Blair Growth Stock Conference on June 5, 2025. Brian Andrews, the CFO, will represent the company during the session. The event will be accessible via a webcast for investors and interested parties, showcasing CooperCompanies' ongoing commitment to investor engagement.
Read more →COOCooperCompanies Appoints Barbara Carbone to Board of Directors
CooperCompanies has appointed Barbara Carbone as an independent director, effective May 1, 2025. Carbone, who has nearly four decades of experience, will also serve on the Audit Committee. Her background includes significant roles at KPMG LLP, where she was an Audit Partner for over 24 years. The Chairman of the Board expressed excitement about her contributions to the company.
Read more →COOCooperCompanies Appoints Cynthia Lucchese to Board of Directors
CooperCompanies Appoints Cynthia Lucchese to Board of Directors SAN RAMON, Calif., October 3, 2022 - CooperCompanies (NYSE: COO) announced today that its Board of Directors has appointed Cynthia Lucchese as an independent director, effective October 1, 2022. Lucchese has also b
Read more →COOCooperCompanies to Acquire Cook Medical s Reproductive Health Business Acquisition will enhance CooperSurgical s international fertility footprint and medical device portfolio.
CooperCompanies to Acquire Cook Medical s Reproductive Health Business Acquisition will enhance CooperSurgical s international fertility footprint and medical device portfolio. SAN RAMON, Calif., February 7, 2022 CooperCompanies (NYSE: COO) today announced it has signed a bind
Read more →COOCooperCompanies Completes Acquisition of Generate Life Sciences
CooperCompanies Completes Acquisition of Generate Life Sciences SAN RAMON, Calif., December 17, 2021 CooperCompanies (NYSE: COO) today announced it has completed the previously announced definitive purchase agreement to acquire Generate Life Sciences, a leading provider of dono
Read more →COOCooperCompanies to Acquire Generate Life Sciences for $1.6 Billion Acquisition will Expand CooperSurgical s Fertility and Labor & Delivery Offerings
CooperCompanies to Acquire Generate Life Sciences for $1.6 Billion Acquisition will Expand CooperSurgical s Fertility and Labor & Delivery Offerings SAN RAMON, Calif., November 10, 2021 CooperCompanies (NYSE: COO) today announced that it has signed a definitive purchase agre
Read more →COOCooperCompanies Elects Maria Rivas, MD to Board of Directors
CooperCompanies Elects Maria Rivas, MD to Board of Directors SAN RAMON, Calif., May 12, 2021 CooperCompanies (NYSE: COO) announced today that its Board of Directors has elected Dr. Maria Rivas as an independent director, effective July 1, 2021. We are pleased to welcome Maria
Read more →About The Cooper Companies, Inc.
Headquarters6101 BOLLINGER CANYON ROAD, SAN RAMON, CA, 94583
BIOPHARMAWATCH ELITE PLUS
Trade the next COO catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime